Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations

Rheumatology (United Kingdom)

Volumn 53, Issue 5, 2014, Pages 919-922

  Henes, Joerg C ^a   Koetter, Ina ^b   Horger, Marius ^a   Schmalzing, Marc ^a   Mueller, Karin ^a   Eick, Christian ^a   Bauer, Axel ^a   Vogel, Wichard ^a   Kanz, Lothar ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Center for Interdisciplinary Rheumatology   (Germany)

Author keywords

CT histography; Cyclophosphamide; Heart; Stem cell transplantation; Systemic sclerosis; Thiotepa; Treatment

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIFUNGAL AGENT; C REACTIVE PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; THYMOCYTE ANTIBODY; THYROTROPIN; TROPONIN I;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIAC IMAGING; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONDITIONING; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LUNG ALVEOLITIS; LUNG DIFFUSION; LUNG FUNCTION TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; RELAPSE; SCLERODERMA; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE;

CT HISTOGRAPHY; CYCLOPHOSPHAMIDE; HEART; STEM CELL TRANSPLANTATION; SYSTEMIC SCLEROSIS; THIOTEPA; TREATMENT;

ADULT; AUTOIMMUNE DISEASES; COMORBIDITY; CYCLOPHOSPHAMIDE; DEFIBRILLATORS, IMPLANTABLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, SYSTEMIC; STEM CELL TRANSPLANTATION; THIOTEPA; TREATMENT OUTCOME; TROPONIN;

EID: 84898793254     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket464     Document Type: Article

References (18)

1. Burt RK, Shah SJ, Dill K et al. Autologous nonmyeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011;378:498-506.
2. van Laar JM, Farge D, Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005;64:1515.
3. Farge D, Labopin M, Tyndall A et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010;95:284-92.
4. Henes JC, Schmalzing M, Vogel W et al. Optimization of autologous stem cell transplantation for systemic sclerosis- a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol 2012;39: 269-75.
5. Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
6. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118:2-10.
7. Elhai M, Meune C, Avouac J et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2012;51:1017-26.
8. Ayash LJ, Wright JE, Tretyakov O et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10:995-1000.
9. Zver S, Zadnik V, Bunc M et al. Cardiac toxicity of highdose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol 2007;85:408-14.
10. Saccardi R, Tyndall A, Coghlan G et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant 2004;34:877-88.
11. Chen TL, Passos-Coelho JL, Noe DA et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/ aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995;55:810-6.
12. Komatsuda A, Kawabata Y, Horiuchi T et al. Successful autologous peripheral blood stem cell transplantation using thiotepa in a patient with systemic sclerosis and cardiac involvement. Tohoku J Exp Med 2006;209:61-7.
13. Giorgetti F, Minnucci ML, Santori P et al. [Autologous peripheral stem cell transplantation in a patient with diffuse systemic sclerosis: our experience]. Reumatismo 2004;56:51-6.
14. Matsuo S, Yamashiro T, Washko GR et al. Quantitative CT assessment of chronic obstructive pulmonary disease. Radiographics 2010;30:55-66.
15. Camiciottoli G, Orlandi I, Bartolucci M et al. Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life. Chest 2007; 131:672-81.
16. Henes JC, Horger M, Amberger C et al. Enteric-coated mycophenolate sodium for progressive systemic sclerosis- a prospective open-label study with CT histography for monitoring of pulmonary fibrosis. Clin Rheumatol 2013; 32:673-8.
17. Rosen O, Massenkeil G, Hiepe F et al. Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide- induced cardiomyopathy. Bone Marrow Transplant 2001;27:657-8.
18. Daikeler T, Labopin M, Di Gioia M et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood 2011;118: 1693-8.